A Phase 1 Randomized, Observer-blind, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G- MARV-GP Vaccine in Adults in Good General Health

The GW Vaccine Research Unit is recruiting volunteers for a study to examine a new vaccine for the prevention of the Marburg virus.

Key Facts about the Marburg Virus:

  • The Marburg virus causes a severe hemorrhagic fever that has a high fatality rate.
  • Marburg Virus Disease occurs in sporadic outbreaks primarily in Sub-Saharan Africa.
  • Currently, there are no approved treatments for the disease.

This study requires participants to attend 9 in-clinic visits over 7 months. To participate in this study, you will receive a vaccine. Those who are eligible and attend the in-clinic visits will receive $75.00 per visit to compensate for time and travel.

Seeking volunteers:

  • Ages 18 - 50
  • Lives in the Washington D.C. metropolitan area
  • In good general health

Fill out interest survey here.

Sponsor(s)
IAVI
Principal Investigator(s)
David Diemert, MD
Contact Phone Number
Request Information

Status message

Sorry… This form is closed to new submissions.